Company intelligence / Profile preview

Affinivax, Inc.

Cambridge (Boston), Massachusetts, United Statesgsk.com ↗

Ownership: Private
Development stage: Phase 2

Overview

In adult Phase I/II clinical trials, their lead vaccine candidate AFX3772 was well tolerated and demonstrated good immune responses compared to the current standard of care. The FDA granted Breakthrough Therapy designation for AFX3772 in July 2021 to prevent S. pneumoniae invasive disease and pneumonia in adults 50 years and above. Phase III preparations were underway as of 2022, and Phase II clinical trials for pediatric use started in June 2022[1][4].

Therapeutic areas: Infectious Diseases
Modalities: Vaccines
Industry: Biotech

Drug pipeline

2 assets

AFX3772

Phase 2

Indications: Pneumococcal disease, Pneumonia, Meningitis, Sepsis

1 more asset in the full pipeline.

Request access →

Partnerships

Boston Children's Hospital (technology license)

Beyond the preview

Go deeper on Affinivax, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Affinivax, Inc..

Explore the full profile